Kanvas Bio Publishes New Research on its Novel Spectral Imaging Platform, a Transformative Tool for Microbiome Drug Discovery and Development
Kanvas Biosciences has published new research demonstrating the capabilities of its High-Phylogenetic-Resolution Spatial Mapping (HiPR-Map) Platform, a spectral imaging technology for microbiome analysis. The platform outperforms conventional sequencing methods with:
- Detection sensitivity of 0.01%
- Species-level microbial identification
- Single-nucleotide resolution of ribosomal RNA
The research revealed three key findings:
- Superior technical performance compared to traditional sequencing
- Detailed engraftment profiles of Live Biotherapeutic Products (LBPs) in mouse GI tract
- Comprehensive mapping of spatial microbial interactions at microscale and mesoscale levels
The technology aims to enhance LBP development for treating conditions ranging from colitis to various cancers, offering advantages over traditional fecal microbiota transplants (FMTs).
Kanvas Biosciences ha pubblicato una nuova ricerca che dimostra le capacità della sua Piattaforma di Mappatura Spaziale ad Alta Risoluzione Filogenetica (HiPR-Map), una tecnologia di imaging spettrale per l'analisi del microbioma. La piattaforma supera i metodi di sequenziamento convenzionali con:
- Sensibilità di rilevamento dello 0,01%
- Identificazione microbica a livello di specie
- Risoluzione a singolo nucleotide dell'RNA ribosomiale
La ricerca ha rivelato tre risultati chiave:
- Prestazioni tecniche superiori rispetto al sequenziamento tradizionale
- Profili di innesto dettagliati dei Prodotti Bioterapici Viventi (LBP) nel tratto gastrointestinale dei topi
- Mappatura completa delle interazioni microbiche spaziali a livello microscopico e mesoscale
La tecnologia mira a migliorare lo sviluppo degli LBP per il trattamento di condizioni che vanno dalla colite a vari tipi di cancro, offrendo vantaggi rispetto ai tradizionali trapianti di microbiota fecale (FMT).
Kanvas Biosciences ha publicado una nueva investigación que demuestra las capacidades de su Plataforma de Mapeo Espacial de Alta Resolución Filogenética (HiPR-Map), una tecnología de imagen espectral para el análisis del microbioma. La plataforma supera los métodos de secuenciación convencionales con:
- Sensibilidad de detección del 0,01%
- Identificación microbiana a nivel de especie
- Resolución de un solo nucleótido del ARN ribosómico
La investigación reveló tres hallazgos clave:
- Rendimiento técnico superior en comparación con la secuenciación tradicional
- Perfiles de injerto detallados de Productos Bioterapéuticos Vivos (LBP) en el tracto gastrointestinal de ratones
- Mapeo completo de las interacciones microbianas espaciales a niveles microscópicos y mesoscópicos
La tecnología tiene como objetivo mejorar el desarrollo de LBP para tratar condiciones que van desde colitis hasta varios tipos de cáncer, ofreciendo ventajas sobre los trasplantes tradicionales de microbiota fecal (FMT).
Kanvas Biosciences는 미생물군 분석을 위한 스펙트럼 이미징 기술인 고급 계통 해상도 공간 매핑 플랫폼(HiPR-Map)의 기능을 입증하는 새로운 연구를 발표했습니다. 이 플랫폼은 기존의 시퀀싱 방법보다 우수한 성능을 보입니다:
- 0.01%의 감지 민감도
- 종 수준의 미생물 식별
- 리보솜 RNA의 단일 뉴클레오타이드 해상도
연구 결과는 세 가지 주요 발견을 보여주었습니다:
- 전통적인 시퀀싱에 비해 우수한 기술 성능
- 생체 치료 제품(LBP)의 생체 내 이식 프로필에 대한 상세한 정보
- 미세 및 메조 규모에서의 공간 미생물 상호작용의 포괄적인 매핑
이 기술은 대장염에서 다양한 암에 이르는 질환 치료를 위한 LBP 개발을 향상시키는 것을 목표로 하며, 기존의 대변 미생물 이식(FMT)보다 장점이 있습니다.
Kanvas Biosciences a publié de nouvelles recherches démontrant les capacités de sa Plateforme de Cartographie Spatiale à Haute Résolution Phylogénétique (HiPR-Map), une technologie d'imagerie spectrale pour l'analyse du microbiome. La plateforme surpasse les méthodes de séquençage conventionnelles avec :
- Sensibilité de détection de 0,01%
- Identification microbienne au niveau des espèces
- Résolution à un seul nucléotide de l'ARN ribosomal
La recherche a révélé trois résultats clés :
- Performance technique supérieure par rapport au séquençage traditionnel
- Profils d'engraftement détaillés des Produits Biothérapeutiques Vivants (LBP) dans le tractus gastro-intestinal des souris
- Cartographie complète des interactions microbiennes spatiales à des niveaux microscopiques et mésoscopiques
La technologie vise à améliorer le développement des LBP pour le traitement de conditions allant de la colite à divers cancers, offrant des avantages par rapport aux transplantations traditionnelles de microbiote fécal (FMT).
Kanvas Biosciences hat neue Forschungsergebnisse veröffentlicht, die die Fähigkeiten seiner Plattform zur Hochphylogenetischen Auflösung der räumlichen Kartierung (HiPR-Map) demonstrieren, einer spektralen Bildgebungstechnologie zur Analyse des Mikrobioms. Die Plattform übertrifft herkömmliche Sequenzierungsmethoden mit:
- Nachweisempfindlichkeit von 0,01%
- Mikrobielle Identifizierung auf Artenebene
- Einzel-Nukleotidauflösung von ribosomaler RNA
Die Forschung ergab drei wichtige Erkenntnisse:
- Überlegene technische Leistung im Vergleich zur traditionellen Sequenzierung
- Detaillierte Einpflanzungsprofile von lebenden biotherapeutischen Produkten (LBPs) im gastrointestinalen Trakt von Mäusen
- Umfassende Kartierung räumlicher mikrobieller Interaktionen auf Mikro- und Mesoskala
Die Technologie zielt darauf ab, die Entwicklung von LBPs zur Behandlung von Erkrankungen von Colitis bis zu verschiedenen Krebsarten zu verbessern und bietet Vorteile gegenüber traditionellen Fäkalienmikrobiota-Transplantationen (FMT).
- Platform demonstrates superior sensitivity (0.01%) compared to traditional methods
- Technology enables precise species-level identification and spatial mapping of microbes
- Platform achieves cost parity with traditional sequencing methods
- Recent addition of Dr. Keith Flaherty (co-founder of Scorpion, acquired by LLY) to Scientific Board strengthens clinical development expertise
- None.
In the paper, Kanvas demonstrates that its technology outperforms conventional sequencing, achieving a sensitivity of
In the treatment of diseases ranging from colitis to various cancers, LBPs represent a crucial advancement over traditional fecal microbiota transplants (FMTs). However, to fully replicate the bacterial complexity and therapeutic potential of natural fecal material, more information beyond merely identifying the microorganisms present is required. Instead, a deeper understanding of microbial interactions – with each other, their host, dietary factors and environmental conditions – is essential. Kanvas' HiPR-Map Platform identifies microbial species, while also delivering comprehensive insights into their functional interactions and dynamics. This extensive level of information allows for precise manipulation and optimization of LBPs, significantly enhancing their therapeutic potential.
"LBPs show great promise for positively modulating the microbiome, a critical component of human health, however existing tools aren't sufficient for developing complex, next generation LBPs," said Dr. Phil Burnham, Chief Scientific Officer at Kanvas. "Kanvas' HiPR-Map technology delivers comprehensive analysis and ultra-high resolution – both optically and taxonomically – while achieving imaging over millimeter-length scales and doing so at cost parity with traditional sequencing. Our latest research shows that our platform can optimize LBP manufacturing and provide a framework for assessing LBPs' therapeutic potential, so that the most effective drugs can be designed and delivered to patients as efficiently as possible."
Kanvas' newly published paper highlights three key findings:
- Superior technical strengths of HiPR-Map in comparison to sequencing: HiPR-Map can detect single nucleotide polymorphisms (SNPs) in the 16S rRNA sequence, enabling species-level microbial identification and achieving a sensitivity of
0.01% that outperforms sequencing, particularly in low-biomass environments. - Engraftment profile of Kanvas LBPs in a mouse GI tract in the ileum, cecum and colon: HiPR-Map revealed host-microbiome-food interactions and showed preferential enrichment of certain species near hosts in different regions of the gut. AIso revealed was microbial enrichment inside or on the boundary of some food particles, which could be used to inform dietary influences on LBP response.
- Spatial interactions of microbes at microscale and mesoscale: At microscale, HiPR-Map showed positive and negative associations of certain species in different regions of the GI tract. At mesoscale, the existence of certain neighborhoods containing varying compositions of different species were found. These distinctive patterns – which would otherwise be lost with sequencing – are vital for LBP manufacturing and evaluating its therapeutic potential.
"HiPR-Map's unparalleled accuracy and exceptional spatial resolution position it as a transformative breakthrough, with potential extending well beyond LBP applications," added Dr. Prateek Sehgal, Senior Principal Scientist at Kanvas Bio. "Kanvas' platform empowers researchers to visualize and dissect complex microbial communities across diverse fields, for instance, providing novel diagnostic insights and advancing the understanding of microbiota in nutritional health."
This research follows Kanvas' November unveiling of data from a clinical trial of FMT and anti-PD-1 re-induction in microsatellite instability-high refractory cancers, the results of which suggest that the gut microbiome affects anti-tumoral immunity in a tumor-agnostic manner. Last month, Kanvas welcomed Dr. Keith Flaherty to its Scientific Board of Directors. A co-founder of Scorpion, which was recently acquired by Eli Lilly (NYSE: LLY), Director of Clinical Research at the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School, Dr. Flaherty will support Kanvas in clinical development and clinical trial design, and help the company build momentum toward a commercial launch of its LBP pipeline.
To access Kanvas' paper in full, click here. For more information on the company or to inquire about leveraging the Kanvas platform for LBP development, visit: www.kanvasbio.com/contact.
About Kanvas Biosciences
Kanvas Biosciences is a spatial biology company building the world's first microbiome drug screening, discovery and manufacturing platform to accelerate the development of next generation live biotherapeutics. With an unparalleled ability to spatially map the microbiome and profile host gene expression, and manufacture complex consortia containing hundreds of members that can restore microbiome health, the company is uniquely positioned to develop novel therapeutics that can significantly improve the lives of all patients living with microbiome-associated diseases. Kanvas Biosciences' technology was initially developed at Cornell University and exclusively licensed. The company's notable investors include DCVC, Lions Capital LLC, FemHealth Ventures, Germin8, Ki Tua Fund, Pangaea Ventures, Triple Impact Capital and Uncommon Denominator. Kanvas Biosciences is headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/kanvas-bio-publishes-new-research-on-its-novel-spectral-imaging-platform-a-transformative-tool-for-microbiome-drug-discovery-and-development-302417178.html
SOURCE Kanvas Biosciences
FAQ
What are the key advantages of Kanvas Bio's HiPR-Map Platform over traditional sequencing methods?
How does Kanvas Bio's technology improve Live Biotherapeutic Product (LBP) development?
What did Kanvas Bio's research reveal about microbial interactions in the GI tract?
What is the clinical significance of Kanvas Bio's recent research for cancer treatment?
